HC Wainwright Issues Pessimistic Forecast for Gossamer Bio (NASDAQ:GOSS) Stock Price

Gossamer Bio (NASDAQ:GOSS) had its price target lowered by HC Wainwright from $10.00 to $5.00 in a research note issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock.

A number of other equities analysts also recently issued reports on the company. The Goldman Sachs Group downgraded Gossamer Bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th. Royal Bank Of Canada raised shares of Gossamer Bio to an “outperform” rating in a research report on Tuesday, February 24th. Barclays cut shares of Gossamer Bio from an “overweight” rating to an “underweight” rating in a research report on Tuesday, February 24th. Oppenheimer dropped their price objective on shares of Gossamer Bio from $12.00 to $3.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, Leerink Partners cut shares of Gossamer Bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $5.43.

Gossamer Bio Stock Performance

Shares of NASDAQ:GOSS opened at $0.52 on Friday. The firm has a market capitalization of $120.77 million, a P/E ratio of -0.76 and a beta of 2.08. The stock has a 50 day moving average price of $2.18 and a 200-day moving average price of $2.59. Gossamer Bio has a 52-week low of $0.33 and a 52-week high of $3.87.

Institutional Trading of Gossamer Bio

Institutional investors have recently bought and sold shares of the company. Legal & General Group Plc purchased a new position in Gossamer Bio in the second quarter worth about $26,000. Ciovacco Capital Management LLC purchased a new stake in shares of Gossamer Bio during the third quarter valued at approximately $27,000. Banco BTG Pactual S.A. bought a new stake in shares of Gossamer Bio during the second quarter valued at approximately $27,000. MMA Asset Management LLC bought a new stake in shares of Gossamer Bio during the fourth quarter valued at approximately $31,000. Finally, Soltis Investment Advisors LLC purchased a new position in Gossamer Bio in the 4th quarter worth approximately $31,000. 81.23% of the stock is owned by hedge funds and other institutional investors.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.